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Background: Since the first methodological publications on adaptive study design approaches in the 1990s, the
application of these approaches in drug development has raised increasing interest among academia, industry and
regulators. The European Medicines Agency (EMA) as well as the Food and Drug Administration (FDA) have
published guidance documents addressing the potentials and limitations of adaptive designs in the regulatory
context. Since there is limited experience in the implementation and interpretation of adaptive clinical trials, early
interaction with regulators is recommended. The EMA offers such interactions through scientific advice and
protocol assistance procedures.
Methods: We performed a text search of scientific advice letters issued between 1 January 2007 and 8 May 2012
that contained relevant key terms. Letters containing questions related to adaptive clinical trials in phases II or III
were selected for further analysis. From the selected letters, important characteristics of the proposed design and its
context in the drug development program, as well as the responses of the Committee for Human Medicinal
Products (CHMP)/Scientific Advice Working Party (SAWP), were extracted and categorized. For 41 more recent
procedures (1 January 2009 to 8 May 2012), additional details of the trial design and the CHMP/SAWP responses
were assessed. In addition, case studies are presented as examples.
Results: Over a range of 5½ years, 59 scientific advices were identified that address adaptive study designs in phase
II and phase III clinical trials. Almost all were proposed as confirmatory phase III or phase II/III studies. The most
frequently proposed adaptation was sample size reassessment, followed by dropping of treatment arms and
population enrichment. While 12 (20%) of the 59 proposals for an adaptive clinical trial were not accepted, the
great majority of proposals were accepted (15, 25%) or conditionally accepted (32, 54%). In the more recent 41
procedures, the most frequent concerns raised by CHMP/SAWP were insufficient justifications of the adaptation
strategy, type I error rate control and bias.
Conclusions: For the majority of proposed adaptive clinical trials, an overall positive opinion was given albeit with
critical comments. Type I error rate control, bias and the justification of the design are common issues raised by the
CHMP/SAWP.
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While the development of statistical methods for the de-
sign and analysis of adaptive clinical trials began more
than 20 years ago [1,2], there is still limited experience
in the application of such designs in clinical trials. Fol-
lowing a workshop at the European Medicines Agency
(EMA) involving academia, industry and regulators in
2007, the Reflection Paper on Methodological Issues in
Confirmatory Clinical Trials Planned with an Adaptive
Design (CHMP/EWP/2459/02) [3] was published. The
US Food and Drug Administration (FDA) followed in
2010, publishing draft guidance on adaptive design clin-
ical trials for drugs and biologics [4]. Because many of
the designs proposed are nonstandard and address the
particular application being considered, and because the
experience of sponsors as well as regulators in planning,
conducting and interpreting clinical trials applying adap-
tive designs is limited, early interaction with regulators
is important. EMA offers developers of medicinal prod-
ucts scientific advice (SA) and protocol assistance (PA)
as formal procedures for such interactions. Protocol as-
sistance denotes the process of providing scientific ad-
vice for designated orphan drugs. For simplicity, in the
remainder of this paper, both procedures (SA and PA)
will both be referred to as scientific advice. SA is pro-
vided by the Committee for Human Medicinal Products
(CHMP) through the Scientific Advice Working Party
(SAWP). In the European Union, it is not mandatory for
sponsors of medicinal products to request SA, and SA is
not legally binding with regard to any future marketing
authorization application of the product concerned, ei-
ther for the regulatory agency, or for the sponsor. SA
can be requested on all scientific aspects of drug develop-
ment (quality, nonclinical and/or clinical issues), including
methodological and statistical issues, during the initial de-
velopment of a medicinal product, as well as later on, dur-
ing the post-authorization phase. Sponsors may ask for
‘follow-up’ to the initial request for SA. The current SA
procedure is streamlined to allow finalization within 40 or
maximally 70 days and includes involvement of the
CHMP by a formalized peer review before final adoption
of the SA letter. Adherence by the sponsor to SA provided
by the CHMP/SAWP has been identified as a predictor of
positive outcome of a marketing authorization application
for pharmaceutical drugs submitted to the EMA [5].
Since 2007 a growing number of scientific advice pro-
cedures relating to adaptive study designs were re-
quested by sponsors. This observation is consistent with
a recent survey by Morgan et al. [6] that noted an in-
crease in the use of more complex adaptive designs for
which early engagement with regulators is encouraged.
The purpose of this survey is to provide an overview on
the type of adaptive designs proposed and the issues that
were identified during the procedures. We assessed thesettings in which adaptive designs were proposed, how
the proposals reflected the provisions of the relevant
guidance documents, and the kind of design methods
used. Furthermore, we report on the CHMP/SAWP po-
sitions on the proposed trial designs.
In Section Regulatory guidance documents, we give a
brief review of the EMA and FDA guidance documents on
adaptive designs (see Gaydos et al. [7] for a detailed discus-
sion), which provide the basis for the assessment of specific
study proposals. In Section Methods, the methodological
background of our survey is presented. In Section Results,
we report results of the survey and discuss several case
studies. Our conclusions regarding the survey are pre-
sented in Section Discussion.
Regulatory guidance documents
In the Reflection Paper on Methodological Issues in Con-
firmatory Clinical Trials Planned with an Adaptive Design
(CHMP/EWP/2459/02) [3], a study design is defined as
adaptive ‘if the statistical methodology allows the modi-
fication of a design element (for example, sample-size,
randomization ratio, number of treatment arms) at an in-
terim analysis with full control of the type I error’. The re-
flection paper emphasizes that the statistical principles for
clinical trials outlined in the ICH E9 guidance document
equally apply to adaptive designs. In particular, besides the
control of the type I error rate (and the familywise type I
error, in settings where several hypothesis are tested, see
the Points to Consider on Multiplicity Issues in Clinical
Trials [8]), it is required that ‘correct estimates and confi-
dence intervals for the treatment effect are available’. An
additional requirement specific to adaptive designs is
that methods for the assessment of homogeneity of
results from different stages are preplanned’. This is of
special concern if the adaptations are based on un-
blinded interim data.
The reflection paper clearly states that interim analyses
need to be justified. To prevent release of interim data,
and thus to protect the integrity of the continuing trial,
the interim analyses should ideally be performed by a
sponsor-independent statistician who provides the ana-
lysis results to a sponsor-independent committee (as de-
fined in the Guideline on Data Monitoring Committees
[9]), which decides on the adaptation to be introduced.
While it is required that the type of adaptations to be
performed are preplanned in the trial protocol, the adap-
tation rule itself does not need to be fixed prospectively.
The Reflection Paper concludes that, in a confirmatory
phase III setting, the additional complexity of adaptive
trials is only justified in ‘difficult experimental situations’
(as, for example, trials in small populations, see EMA
Guideline on Clinical Trials in Small Populations [10]),
and the reasons an adaptive design is proposed need to
be described in detail.
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statistical approaches for clinical trials with an adaptive
interim analysis but formulates general minimal require-
ments that the methods need to satisfy. Several statistical
methods have been developed that allow mid-trial design
modifications in multistage designs that are based on
unblinded interim data without compromising the type I
error rate. Some approaches rely on detailed algorithmic-
ally pre-specified adaptation rules, while more flexible
methods, as for example, adaptive combination tests [1]
or the conditional error approach [2,11] (which are closely
related [12]), control the level without a detailed pre-
specification of the adaptation rule.
While the EMA document focuses on the use of adap-
tive designs in the confirmatory setting, the FDA draft
guidance Adaptive Design Clinical Trials for Drugs and
Biologics [4], published in 2010, also discusses the use of
adaptive designs in earlier phases of drug development
and encourages their use in this setting. For confirma-
tory trials, the FDA document distinguishes between
‘well understood’ and ‘less well understood’ (due to lim-
ited experience of sponsors and regulators) adaptive
designs. The latter category comprises mainly adaptive
designs where adaptations are based on unblinded in-
terim data. Similar to the EMA document, the FDA draft
guideline states that type I error rate control is a primary
statistical concern of a confirmatory adaptive clinical
trial. In addition it is emphasized that unblinded interim
analyses in a confirmatory settings raise concerns that
access to unblinded data of persons involved in the con-
duct of the study may cause operational bias, thereby
compromising the integrity of the trial. Overall the EMA
and FDA documents share the same major principles.
Methods
A text search of scientific advice letters issued between
January, 1, 2007 and May 8, 2012 containing one of the
following key terms: ‘adaptive design’; ‘flexible design’;
‘adaptive interim analysis’; ‘sample size reassessment’;
‘adaptive group sequential’ and ‘CHMP/EWP/2459/02’
(CHMP Reflection Paper on Methodological Issues in
Confirmatory Clinical Trials Planned with an Adaptive
Design) was performed. The resulting letters were reviewed
and letters containing questions related to adaptive clinical
trials in phases II or III were selected for further analysis.
Based on the selected letters, details of the procedure (type
of product, therapeutic area, rare disease, that is, a
prevalence of <5/10,000, designation as orphan medi-
cine, small- or medium-size enterprise status of the
company (SME), year of the scientific advice, whether
the study in question was a single pivotal study), the
proposed adaptive study (type of primary endpoint,
phase II or phase III study, initial number of study arms
included, stopping for futility or efficacy, number ofinterim analyses, type of adaptations), and the CHMP/
SAWP response were categorized.
We classified the CHMP/SAWP responses into three
categories: ‘accepted’ for proposals where no major crit-
ical issue was identified and the adaptive trial proposal
was endorsed; ‘accepted conditionally (concerns to be ad-
dressed)’ for procedures where the adaptive design pro-
posal was endorsed in principle but critical issues were
raised that need to be resolved before the trial can be en-
dorsed; and ‘not accepted’ for proposals where CHMP/
SAWP recommended a different experimental approach.
For the more recent procedures (1 January 2009 to 8
May 2012), additional details of the trial design were
assessed. Note that the search strategy identified only
scientific advice letters discussing clinical trials with de-
sign modifications at an interim analysis where at least
one of the search terms occurred. Thus, the reported
numbers give only a lower bound for the actual number
of scientific advices given on adaptive designs. For ex-
ample, an earlier review [13] identified 16 and 15 scien-
tific advice letters on confirmatory adaptive designs for
the years 2007 and 2008, respectively, using a different
search strategy. Even though the absolute numbers of
SA letters were different, the key findings were similar.
Our research did not involve individual human data as
the survey was restricted to official scientific advice texts
on statistical methodology. According to the publication
policy of the EMA, the manuscript was approved by the
EMA review board.
Results
Characteristics of submitted studies
The text search identified 123 (83 from 1 January 2009
to 8 May 2012) scientific advice letters, of which 59 (41)
addressed questions on an adaptive design for a phase II
or phase III trial. Figure 1 shows the number of such
procedures per year. There appears to be an increase in
submissions in 2011 (note that the numbers for 2012 in-
cludes the data till May, 8 only), possibly an impact of
the publication of the FDA guidance document in 2010.
About two-thirds of the procedures were on clinical
trials for new biologicals, new chemicals or advanced
therapies, and the remaining were on known medicinal
products. A total of 27 (46%) of the trials were performed
in oncological indications, 35 (59%) on a rare disease, but
only 21 (36%) had an orphan designation (see Table 1 for
the descriptive statistics of all variables). A total of 15
(25%) of the requests for scientific advice were from
small- and medium-sized enterprises. Almost all of the
clinical trials (54, 92%) were planned as confirmatory trials
and labelled as phase III or phase II/III studies. In 44
(75%) of the procedures, the adaptive clinical trial was
proposed as the only pivotal study to be performed. A
total of 30 out of these 44 proposals (68%) with a single
Figure 1 Number of identified scientific advice (SA) and
protocol assistance (PA) procedures per year. The projection for
2012 (light gray) is based on linear extrapolation of the number of
submissions received in 2012 until May 8, assuming the submission
rate stays constant.
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30 actually had the orphan designation.
Most sponsors (43, 73%) proposed trials with a single
interim analysis. While a futility rule was discussed in
the scientific advice letter for 31 (53%) trials, only 19
trials (32%) planned for early stopping for efficacy.
The most frequently proposed adaptation was sample
size reassessment (43, 73%), followed by dropping of
treatment arms (19, 32%) and population enrichment
(5, 8%).
In 17 (29%) of the 59 proposed adaptive trials, options
to stop the trial in the interim analysis for both efficacy
and futility were pre-planned; in 14 (24%), early stopping
was allowed for futility only. For the 43 trials with sam-
ple size reassessment, the respective frequencies are 15
(35%) and 24 (56%). Furthermore, of the 43 trials with
sample size reassessment, 7 (16%) additionally included
the option to drop a treatment arm.
In the more recent procedures (41 procedures from 1
January 2009 to 8 May 2012), where additional items
were assessed, see Table 2), we found that 33 (80%) trials
were proposed with an unblinded interim analysis in
which the proposed design adaptations are based on
unblinded interim data. Interestingly, two of the studies
included a blinded as well as an unblinded interim
analysis. For the majority of studies, the interim analysis
was planned to be performed by an external data safety
monitoring board, an independent statistician or a con-
tract research organization (25, 61%).Outcome of the Committee for Human Medicinal Products/
Scientific Advice Working Party advice
While 12 (20%) of the 59 proposals for an adaptive
clinical trial were not accepted, the great majority of the
proposals were accepted (15, 25%) or conditionally ac-
cepted (32, 54%). In 19 (32%) of the advice letters the
CHMP/SAWP raised issues regarding type I error rate
control. In 12 (29%) of the more recent 41 procedures,
the CHMP/SAWP raised concerns that the adaptation
strategy was not sufficiently justified. In six (15%) of the
advices it was stated that a single pivotal trial that is
adaptive is not recommended for the development pro-
gram considered. For 12 (29%), a concern regarding type
I error control was raised, whereas in 12 (29%), it was
stated that results could potentially be biased, for example,
because of the selection of treatment arms. A too-large
number of interim analyses were considered to be of con-
cern in two of the procedures. Another common concern
was that the extent of reflection and adaptation required
at the end of phase II will be too extensive to make a
phase II/III ‘seamless’ trial practical.
Case studies
In this review, we present three illustrative examples on
how adaptive designs were proposed by sponsors for
real-case scenarios of planned pharmaceutical develop-
ment program. All case studies presented here were dis-
cussed at scientific advice meetings between 2007 and
2012. We focus on the response of the CHMP/SAWP
concerning the adaptive features of the proposed clinical
trial designs: that is, the review is fully based on the SA
answer letter the sponsor received at the end of the SA
procedure. The case studies shall illustrate how a spon-
sor can interact early with regulators and how critical is-
sues can be addressed.
Case study 1: sample size reassessment
The first case study concerns an open-label, two-armed,
single pivotal phase III study of an anticancer drug for a
rare disease. The study was planned to show superiority
of the drug over a standard treatment for the primary
endpoint of overall survival. The adaptive design was
pre-planned and two interim analyses were intended to
be performed by an independent data monitoring com-
mittee. The interim analyses were intended to be per-
formed at 50% and 80% of events, given a fixed overall
sample size.
At the second interim analysis, the sponsor planned to
re-evaluate the targeted number of events and suggested
an increase in the number of events by 20% if the in-
terim results show a promising but not overwhelming
trend. The event number was to be increased without
increasing the sample size by extending the observation
period. The decision to increase the number of events
Table 1 Descriptive Statistics of the scientific advice (SA)/protocol assistance (PA) procedures in the years 2007 to 2012
Variable N (%)
Number of SA/PA letters with questions on adaptive phase II,
phase II/III or phase III designs
59 (100%)
Type of medicinal product New chemical entity 23 (39%)
Known chemical entity 13 (22%)
New biological 13 (22%)
Known biological 6 (10%)
Advanced therapy 4 (7%)
Therapeutic area of the indication of the medicinal product Infectious disorders 4 (7%)
Oncology 27 (46%)
Endocrine and metabolic disorders 3 (5%)






Rare disease (prevalence of <5/10,000) 35 (59%)
Applied for orphan designation 21 (36%)
Small or medium enterprise 15 (25%)






Scale of measurement of the primary endpoint discussed Time to event 28 (47%)
Binary 20 (34%)
Continuous 11 (19%)
Adaptive study is the only pivotal trial 44 (75%)
Development phase for which the adaptive clinical trial is proposed Phase II or IIb 4 (7%)
Phase II/III 16 (27%)
Phase III 38 (64%)
Pediatric study 1 (2%)




Stopping for futility was planned for in the adaptive trial Yes 31 (53%)
Stopping for efficacy was planned for in the adaptive trial Yes 19 (32%)
Number of interim analyses planned in the adaptive trial 1 43 (73%)
2 13 (22%)
>2 3 (5%)
Elsäßer et al. Trials 2014, 15:383 Page 5 of 10
http://www.trialsjournal.com/content/15/1/383
Table 1 Descriptive Statistics of the scientific advice (SA)/protocol assistance (PA) procedures in the years 2007 to 2012
(Continued)
Type of adaptations planned (multiple answers possible) Sample size reassessment 43 (73%)
Population enrichment 5 (8%)
Dropping of treatment arms 19 (32%)
Other adaptations 4 (7%)
CHMP raised issues regarding type I error rate control 19 (32%)
Categorization of the CHMP advice regarding the adaptive study design Accepted 15 (25%)
Accepted conditionally (concerns to be addressed) 32 (54%)
Not accepted 12 (20%)
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board, which would receive unblinded interim data.
Based on the interim results, the conditional probability
to obtain a significant result at the end of the study was
to be estimated under various assumptions on the survival
distribution and effect sizes. In particular, a bootstrap-
based method taking into account the empirical survival
distribution function was considered. Furthermore, in both
interim analyses, Haybittle-Peto stopping boundaries for
early rejection of the null hypothesis were pre-planned. To
control the type I error rate, the sponsor proposed to use
the inverse normal method, which combines the data
accrued before and after the interim analysis in a pre-Table 2 Additional variables, years 2009 to 2012
Description
Number of scientific advice (SA) and protocol assistance (PA) letters with
questions regarding adaptive phase II or phase III designs
Number of pivotal studies the company plans to conduct.
Adaptive design was preplanned in advance of the conduct of the study
The planned interim analyses will be performed in a blinded fashion
Interim analyses are to be performed externally (for example, by an external
data safety monitoring board, an independent statistician or a contract
research organization)
Issues raised in the Committee for Human Medicinal Products (CHMP) answe
regarding the proposed adaptive design (the issues raised relate both to
designs that were conditionally accepted and those not accepted, multiple
answers possible)specified way [14,15]. The CHMP/SAWP stated that the
design is acceptable from a statistical point of view if the
type I error rate is controlled and operational bias is
avoided. Based on concerns over the totality of evidence
that would be available for a benefit-risk assessment, the
CHMP/SAWP experts did not agree on the early stopping
boundary to reject the null hypothesis in the first interim
analysis, and stated that at the first interim analysis, the
trial should be stopped for futility only.
For the analysis of the adaptive trial, the CHMP/SAWP
requested a comparison of the treatment arms based on
the standard fixed sample test statistics and that the spon-










No information 3 (7%)
Blinded and unblinded 2 (5%)
No 5 (12%)
Yes 25 (61%)
No information 11 (27%)
r Adaptation strategy not sufficiently justified 12 (29%)
Potentially biased results 12 (29%)
Too many interim analyses 2 (5%)
A single pivotal trial which is adaptive is not
recommended
6 (15%)
Control of type I error rate 12 (29%)
Other issues 5 (12%)
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verse normal method down-weights the treatment effect
observed in the second stage if the number of events is in-
creased. If the sample size is increased only if a promising
interim effect is observed, it has been shown that under
suitable conditions the fixed sample test controls the type
I error rate [16,17]. In addition, in the application to
survival data, the additional events will typically occur at
later time points. Therefore, under alternative hypotheses
where the survival curves initially separate but become
closer at later time points, down-weighting the second
stage test statistics (based mainly on late stage events) was
considered undesirable. Note that an additional complex-
ity of the proposed design, which was not explicitly dis-
cussed in the SA procedure, is the issue that sample size
adaptations based on information of patients censored at
the interim analysis may lead to an inflation of the type I
error rate [18-20].
Case study 2: interim dose selection
The second case study is a proposal of seamless phase
II/III designs for two pivotal placebo controlled super-
iority trials of a new chemical entity for the treatment of
diabetic nephropathy, which were supposed to be con-
ducted in parallel. The proposed primary efficacy param-
eter was a surrogate marker of kidney disease progression.
The purpose of the adaptive design was to eliminate one
of three initially tested dose strengths based on an interim
analysis of the benefit/risk ratio in both trials. In this man-
ner, the sponsor intended to seamlessly combine dose
finding/refinement and pivotal testing for efficacy and
safety. The interim analyses were pre-planned and to be
performed by an independent data monitoring committee
(IDMC) after 60% of 420 patients had completed 8 weeks
of treatment (primary analysis for efficacy and safety
planned for week 24, secondary analysis at week 52) in the
first trial. At the time of the interim analysis, it was ex-
pected that in the second trial about 40% of patients
would have been recruited. The decision on dose selection
was to be performed based on interim data from both tri-
als using pre-determined criteria for the primary efficacy
and safety parameters. In addition, the interim analyses
were intended for the identification of a single dose for a
renal event outcome trial. In order to preserve trial integ-
rity, the company proposed that the IDMC’s decision to
eliminate one dose strength was to be implemented by a
pre-created interactive voice response system to avoid
communication of this information to the sponsor. How-
ever a dose recommendation for an additional renal out-
come trial was to be communicated from the IDMC to
the sponsor. With regard to the type I error rate, the spon-
sor proposed to use a Bonferroni adjustment to control
the familywise error rate at a two-sided level of 5%. Be-
cause in the final analysis only two doses were to be testedand no early stopping of the study was foreseen, the spon-
sor suggested adjusting the level for two comparisons only
and applying a two-sided Bonferroni adjusted level of
0.05/2 = 0.025 for each comparison. The statistical testing
procedure was not endorsed, as it was not supposed to
control the familywise type I error rate for the three
hypotheses initially considered. Even though, in the final
analysis, only two doses would be compared to placebo,
these two doses were to be selected based on interim
treatment effect estimates of three dose arms. This selec-
tion may lead to a biased test unless an appropriate adjust-
ment is made. In this case, adaptive combination tests
based on the closure principle [21-23] and adaptive
Dunnett test [24] procedures based on the conditional
error rate have been proposed by the CHMP/SAWP as
valid methods. Furthermore, it was suggested that the
sponsor should evaluate the advantage of the proposed
design with respect to power and sample size compared
to more standard design options as the improvement in
efficiency may be small when taking into account the time
needed for the conduct of interim analyses and decision
making. Furthermore, it was questioned whether adequate
safety evaluation would be possible to support dose selec-
tion at the proposed time of interim analysis. Finally, the
communication of a single dose to be tested in the renal
event outcome trial was considered as an overall risk to
the integrity of the development program as it would have
necessarily revealed some degree of information about the
interim data.
Case study 3: post-hoc adaptations
The third case study was an open-label, two-armed, sin-
gle pivotal phase III study of a new chemical drug for
treatment of advanced ovarian cancer resistant or refrac-
tory to a defined chemotherapy. The study was planned
to show superiority over an active control for the pri-
mary endpoint of progression-free survival (PFS) deter-
mined by an Independent Review Committee (IRC).
Even though the study was an open label study, the
sponsor had no access to randomization or treatment
codes.
Although the active control was considered acceptable
and had been licensed in the EU for the proposed indica-
tion, information on the effect size in the intended popu-
lation was limited to small subgroups of patients. Thus,
during the planning stage of the study, the sponsor had to
determine sample size and power based on very limited
data for estimated PFS of the active control. Estimated
PFS for the test drug was based on results of a small phase
II study in fewer than 30 patients. During the ongoing
pivotal phase III study when patient accrual had been
completed, external data from a well-designed study in
the target population found PFS for the active control
drug to be considerably longer (approximately 50%) than
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accordance with the IDMC charter, the sponsor periodic-
ally reviewed aggregate blinded investigator-reported PFS
data and found a median PFS significantly longer than the
original expected median PFS estimate both for the active
drug and the control.
In order to reduce the risk of a potentially underpow-
ered study, the sponsor proposed to increase the number
of IRC-determined PFS events for the final analysis from
254 events to 375 events based on the revised assump-
tion on estimated longer PFS in the control group and
preservation of the relative treatment effect by the active
drug. The sponsor believed there was no impact on the
type I error when performing the originally planned fixed
sample test because the sample size adjustment was only
based on blinded interim data and external information.
The CHMP/SAWP had no objections against the se-
lected comparator in a superiority trial or the revised
assumption regarding PFS. Furthermore, there was no
concern regarding an inflation of the type I error for the
final analysis. However, the CHMP/SAWP noted that the
final estimates of the treatment effect might be affected by
some (small) bias due to the sample size reassessment.
Discussion
Adaptive clinical trials are a frequently considered de-
sign option for clinical trials proposed by sponsors who
request scientific advice. Asking for scientific advice on
innovative trial designs is an attractive way for sponsors
to involve regulatory agencies already in the planning
aspects of a clinical drug development program. In
addition, a new option to discuss statistical methodology
more broadly, and not specifically for a certain clinical
trial, is the recently introduced EMA procedure for the
‘Qualification of novel methodologies for medicine de-
velopment’ [25], which includes statistical methodology
as well. The survey illustrates that for the majority of
proposed studies, CHMP/SAWP gave an overall positive
opinion albeit with critical comments. In general our re-
view confirmed that scientific advices issued are in line
with the CHMP reflection paper on adaptive designs.
The CHMP/SAWP stressed on many occasions that in
confirmatory clinical trials the number of adaptations
and interim analyses should be kept to a minimum and
will have to be thoroughly justified in each case.
However, even though a huge range of statistical meth-
odology to avoid type I error inflation in adaptive clinical
trials has been developed over the years, type I error
control in adaptive clinical trials surprisingly is still a
frequent major concern raised in the SA letters. For ex-
ample, the testing strategy outlined in case study 2 (no
multiplicity adjustment for the initially considered but
dropped treatment arms) is a common but erroneous
approach for multiarmed clinical trials with adaptiveselection of treatment arms [26,27]. Therefore, CHMP/
SAWP’s refusal to endorse adaptive designs without strict
type I error control is not based on a negative position to-
wards adaptive designs per se but reflects that type I error
control in confirmatory clinical trials is considered of key
importance. Therefore, when discussing adaptive designs
the sponsor should demonstrate that the statistical ap-
proaches chosen control the type I error.
A further issue raised in the scientific advice letters is
the requirement for a sound justification for the planned
adaptations. To justify why an adaptive clinical trial is a
favorable design option, extensive simulation studies are
typically required, where the operating characteristics of
the adaptive design are compared to more classical ap-
proaches as fixed sample trials or several trials in sequence.
While adaptive designs may increase the statistical effi-
ciency, the additional complexities of such designs increase
risks to the integrity of the trial. Therefore, a justification is
required that demonstrates that potential advantages of the
more complex design outweigh the risks.
An unexpected finding was that in a majority of the
proposals the adaptive clinical trial is the only pivotal
trial mentioned in the scientific advice request, but this
raised concerns in only a few cases even though the
EMA reflection paper on adaptive designs [3] in general
does not endorse the application of adaptive designs in
single pivotal trials. However, for orphan indications, the
reflection paper notes that a single adaptive trial may be
justified ‘if such an approach is more efficient to display
the totality of available information’. Indeed, a large
fraction of the submitted proposals focus on orphan in-
dications. However, they also include other indications
(oncology, in particular) where a single pivotal trial is
the norm because a demonstration of superiority pre-
cludes further randomization against that comparator.
Also, there are specific challenges to obtain sufficient in-
formation from standard phase II exploratory trials. The
survey demonstrates that the scientific advice and proto-
col assistance process individually assesses proposals on
a case-by-case basis where sponsors do not routinely fol-
low the reflection paper. In the European regulatory sys-
tem, the pivotal studies constitute the core of regulatory
decision making for marketing authorizations, and the
EMA reflection paper focuses on confirmatory adaptive
designs. This may motivate sponsors to discuss the use
of adaptive trial designs when used in later phases of
drug development but not when they are used for in-
ternal decision making, as proof of concept or dose
finding studies. Even though not explicitly mentioned in
the reflection paper, the EMA generally also encourages
the use of innovative methods in earlier stages of drug
development. Besides the SA and PA procedures, the
Agency provides nonproduct-related platforms such as
Innovation Task Force Meetings, Scientific workshops
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logical approaches. Sharing experience between spon-
sors and regulators also for exploratory adaptive trials
can be of great value, not least because in some areas,
exploratory trials may constitute the majority of adap-
tive trials performed.
Conclusions
It is difficult to draw general inferences about regulatory
standards and preferences from the case studies and the
survey because the assessment by the SAWP and CHMP
depends on the overall quality and the general context
of the proposal (overall drug development program, type
of medicinal product, indication, etcetera). However, there
are a number of questions that are generally addressed by
assessors when evaluating adaptive clinical trial proposals:
1. Is there a good rationale? Have alternative, more
standard trial designs been considered?
2. Does the proposal fit well in the context of the
development program and the data that will be
available for the marketing authorization
application?
3. Can the proposal be implemented without
important damage to trial integrity?
4. Is the type I error rate controlled?
5. Has the potential bias of treatment effect estimates
been evaluated?
6. Is the proposal practical and feasible?
Such questions are not specific for adaptive clinical
trial designs but may also be asked of more conventional
approaches. However, for adaptive designs, the assessment
is typically more complex. Therefore, adaptive design pro-
posals are regularly referred to EMA’s Biostatistics Work-
ing Party, which comprises statistical experts from the
European regulatory expert network and also includes ex-
perts from academia. Regulators involved in scientific ad-
vice and protocol assistance procedures have to be aware
of the latest scientific developments in statistical method-
ology and study designs when giving advice to sponsors.
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